Vectura drug delivery, pulmonary, neurology news

Vectura will restructure its R&D operations and reduce headcount by about 85 (31%) to 190 to focus on partnered programs and branded generics. Vectura will seek licensing partners for its existing specialty products, including VR040, an inhaled apomorphine in Phase II testing to treat Parkinson's disease (PD); and VR496, an inhaled mucolytic agent in Phase II testing to treat cystic fibrosis (CF). ...